TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial and operating results for the first quarter 2008. The Company reported a net loss of $11.6 million, or $0.15 per share (basic and diluted), for the first quarter of 2008 compared with a net loss of $29.9 million, or $0.46 per share (basic and diluted), for the first quarter of 2007.
